SAGE Therapeutics

215 First Street
Cambridge
Massachusetts
02142
United States

Tel: 617-299-8380
Fax: 617-299-8379

Email: contact@sagerx.com

Show jobs for this employer

About SAGE Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, brexanolone (SAGE-547), is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com.

194 articles with SAGE Therapeutics